17-Nov-2026 19:36:21
GLENMARKGeneral news
GLENMARK : IGI SUBMITS IND TO US FDA FOR ISB 2301
• Ichnos Glenmark Innovation (IGI) submitted an Investigational New Drug application to the U.S. FDA for ISB 2301 • ISB 2301 is a first-in-class pentaspecific immune cell activator targeting three tumor-associated antigens and engaging both T cells and NK cells • Molecule engineered using IGI's proprietary BEAT Multispecific Platform; preclinical studies showed favourable pharmacokinetics and tolerability in non-human primates • IGI plans to initiate a Phase 1 trial in patients with solid tumors in 2027 • Filing is a regulatory milestone only; no deal value or financial terms disclosed
Glenmark Pharmaceuticals Limited
Open attachment